Popular Trials
Virus Therapy
LAIV for Flu
This trial is testing the hypothesis that the T-bet expressing fraction of flu-specific B cells after receiving the live attenuated influenza vaccine (LAIV) serves as an early biomarker of long-lived antibody responses after vaccination.
Virus Therapy
Flu Vaccine for Elderly Immune System
This 5-year proposal is a randomized study of split-virus influenza vaccine (SVV) in a high-dose (HD) vs. standard-dose (SD) formulation in each of five influenza seasons to define the key determinants of vaccine-mediated protection against influenza and how these immunologic mediators may be enhanced by vaccination with a newly approved high-dose influenza vaccine in older people
Vaccine
HD Vaccine +1 More for Influenza
The purpose of this study is to prospectively evaluate relative effectiveness of high dose influenza vaccine in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the standard dose trivalent seasonal influenza vaccine.
Group B for Influenza
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu. Public health campaigns advocate widespread vaccination for the flu, and especially for high risk people. People with cancer are high risk, with an increased risk of developing complications from the flu, such as pneumonia, bronchitis, or worsening of other medical conditions. As part of their vaccination campaign, the CDC strongly encourages inpatients to be vaccinated prior to hospital discharge. Accordingly, Stony Brook Hospital has enacted a policy that mandates screening all hospital inpatients for vaccination prior to discharge. While physicians or patients can opt not to vaccinate, the default is to proceed. Surgical oncologists have several concerns about vaccinating their patients after major surgical procedures. Patients with cancer have impaired immunity, and the ability of our patients to mount an effective immune response to the vaccine is unclear. Conversely, due to their immunocompromised state, our patients may be more susceptible to complications from the vaccine, such as influenza-like-illness (ILI), or have higher rates of postoperative complications due to the additional immune challenge of the vaccine. Previous studies have evaluated the flu vaccine in patients receiving chemotherapy, or after organ transplantation, but the combination of cancer and major surgery remains unstudied. This is a collaborative study with Infectious Diseases and Microbiology to evaluate the response to the flu vaccine in patients with pancreatic or gastric cancer, soft tissue sarcoma or peritoneal surface disease (i.e. carcinomatosis from appendiceal or colon cancers). Patients will be randomly selected to receive the vaccine either 2 weeks preoperatively or postoperatively at the time of discharge. Serum antibody response, rates of ILI and post-op complications will be analyzed. The long term goal of this study is two-fold: to determine the optimal time to vaccinate this group of patients in relation to their surgery, and to improve compliance with vaccination.
Interferon
Interferon alfacon-1 for Influenza
A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating Influenza Viruses. The use of Interferon-alfacon1 as a co-treatment along with the standard of care antiviral is hypothesized to be safe. Clinical improvement of patients is hypothesized to be quicker.
Popular Filters
Phase 3 Trials
Probiotic
Bifidobacterium lactis HN019 for Influenza
To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.
Virus Therapy
modRNA Vaccine for Flu
This trial is testing a new type of flu shot that uses modified RNA to protect against four strains of the flu. It targets healthy adults aged 18 and older. The vaccine works by teaching the immune system to recognize and fight the flu virus.
Cancer Vaccine
Combined Vaccine for COVID-19 and Flu
This trial is studying the safety and effects of a combined influenza and COVID-19 vaccine. The goal is to see if giving both vaccines at the same time can provide better protection against both diseases. Around
Anti-viral
Baloxavir Marboxil for Flu
This trial is testing a flu medicine called baloxavir marboxil in children aged 1 to under 12 years. The medicine is given as a single dose and aims to stop the flu virus from spreading in the body, making the illness less severe and shorter. Baloxavir marboxil has been shown to reduce the duration of influenza symptoms by approximately one day.
Trials With No Placebo
Behavioral Intervention
Digital Storytelling for Flu Vaccination in Children
This trial aims to address the unequal impact of seasonal influenza on Black children by developing and testing a Digital Storytelling intervention to increase influenza vaccination rates in Black children aged 6 months to 5 years
Trials Offering Remuneration
Virus Therapy
VAX2012Q for Influenza
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40 years of age.
Virus Vaccine
Inactivated Influenza A/H5N1 Vaccine for Influenza
This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.
Adjuvant
MAS-1 +1 More for Flu
The purpose of this study is to evaluate the safety, tolerance, and immunogenicity of MAS-1-Adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted comparator IIV standard dose (SD) in healthy adults and high dose (HD) IIV in ambulatory elderly subjects. Hypothesis: Reduced HA dose IIV formulated in MAS-1 adjuvant (MER4101) has been shown under Phase 1A to be safe, tolerable and demonstrated a more robust and durable immune response to IIV over 6 months post-vaccination in healthy young adults 18 - 49 years of age compared to SD IIV. Under phase 1B, the 9 µg/HA dose of IIV in 0.3 mL MAS-1 was safe and well tolerated and immunogenically comparable to or better than 60 µg/HA HD IIV control over 3 to 6 months post-vaccination than HD IIV control. It is anticipated that the increased total dose of 15 µg HA antigen administered concurrently to opposite arms in 2 doses of 7.5 µg/HA IIV in 0.25 mL MAS-1 adjuvant emulsion will be safe, well tolerated, and more immunogenic than 9 µg/HA IIV in MAS-1, and will be more immunogenic when compared to HD IIV control in adults who are 65 years of age and older with the potential to provide better protection throughout the influenza season.
View More Related Trials
Frequently Asked Questions
Introduction to influenza
What are the top hospitals conducting influenza research?
In the ongoing battle against influenza, several hospitals have emerged as leaders in conducting clinical trials to combat this infectious disease. The National Institutes of Health (NIH) Clinical Center in Bethesda is at the forefront, with four active influenza trials and a total of 15 conducted over time. Notably, their first recorded influenza trial dates back to 2008, showcasing their long-standing commitment to research in combating this seasonal menace. Another institution making strides is Johnson County Clin-Trials located in Lenexa. With four ongoing influenza studies and an impressive history of 19 previous trials, they have been dedicated to finding innovative solutions since their inaugural influenza trial in 2007.
Meanwhile, Meridian Clinical Research LLC based in Omaha has been contributing significantly with three active influenza trials and a track record of successfully completing 12 such studies since commencing research on the virus back in 2004. Closer home at CTI Clinical Research Center situated in Cincinnati; they may currently be running only three investigations but had made pioneering leap forward by recording its debut experiment concerning flu cases right from2022 onwards
Finally yet importantly Insight Therapeutics LLC located at Norfolk also actively carries out three current scientific inquiries into flu cases while already having accomplished progress through five prior tests upon beginning from2013 itself.
These esteemed hospitals serve as crucial hubs for advancements not just within local communities but across the nation's collective fight against this contagious respiratory illness. By participating or administering these clinical trials patients not only gain access to potentially life-saving treatments but also become integral contributors toward future breakthroughs that can ultimately help protect millions globally
Which are the best cities for influenza clinical trials?
In the realm of influenza clinical trials, several cities emerge as key players in advancing research and treatment. Miami, Florida leads with 24 ongoing trials investigating various approaches such as SSA: bivalent BNT162b2 (dose level 1) + QIV and mRNA-1010. Omaha, Nebraska follows closely behind with 18 active studies exploring interventions like Quadrivalent influenza modRNA vaccine. Rochester, New york also boasts 18 ongoing trials evaluating options such as VAX-MOM Intervention and Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose. Lastly, San Diego, California contributes to the field with its 17 active trials examining advances like Group 2: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 2. These cities offer fertile ground for cutting-edge research aimed at improving our understanding and management of influenza.
Which are the top treatments for influenza being explored in clinical trials?
In the realm of influenza research, several top treatments are currently under exploration in clinical trials. The first on the list is the Influenza Vaccine, which shows promise with four active trials and a total of 13 all-time influenza trials since its debut in 2008. Another contender making waves is Baloxavir, involved in two ongoing studies and listed for the first time in 2020. Equally noteworthy is Baloxavir Marboxil, also participating in two active trials and accumulating nine all-time influenza trials since its introduction in 2016. Lastly, we have High Dose Quadrivalent Inactivated Influenza Vaccine joining the ranks with two current trials underway after being listed just this year (2021). As researchers delve deeper into these innovative treatments, hope grows stronger for improved outcomes against influenza outbreaks worldwide.
What are the most recent clinical trials for influenza?
Recent clinical trials for influenza have introduced promising advancements in the field. Notably, Group i and Influenza Vaccine studies have reached Phase 4, indicating their advanced stages of testing. Additionally, Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine and Fluad investigations are progressing well in Phase 2 trials. Furthermore, Arm 2 is currently undergoing Phase 1 testing to evaluate its potential effectiveness against influenza. With these ongoing studies focused on developing effective treatments and prevention strategies for influenza, there is hope for improved management of this infectious disease in the near future.
What influenza clinical trials were recently completed?
Several recent clinical trials focused on influenza have reached completion, representing significant advancements in combating this infectious disease. In August 2022, Seqirus successfully concluded a trial evaluating the efficacy of Experimental: aIIV-B Investigational as a single intramuscular dose. Preceding that, in July 2022, Seqirus completed a trial for aH5N6c. Other notable completed trials include FluGen Inc.'s investigation into the Cam2020 M2SR H3N2 influenza vaccine (June 2022), ModernaTX's mRNA-1073 study (May 2022), and Janssen Vaccines & Prevention B.V.'s Ad26.COV2.S research (November 2021). These studies stand testament to ongoing efforts to develop effective treatments against influenza and safeguard public health.